血清炎性标志物对非小细胞肺癌免疫治疗的预测价值

Predictive value of serum inflammatory markers in immunotherapy of non-small cell lung cancer

免疫检查点抑制剂(ICI)不仅能在短时间内延长非小细胞肺癌(NSCLC)患者的生存时间, 甚至还能对肿瘤实现持久应答。然而, ICI的疗效在不同类型NSCLC患者中存在显著异质性, 目前仍缺乏普遍的生物标志物来预测ICI治疗的获益情况。炎症在肿瘤的发生发展中起一定作用, 血清中多种炎性标志物也成为反映免疫状态的临床指标, 如乳酸脱氢酶、C反应蛋白、血清中性粒细胞、淋巴细胞、血小板等指标。这些炎性标志物简单易得, 与多种实体肿瘤的预后相关。

Immune checkpoint inhibitors(ICIs)can not only prolong the survival time of patients with non-small cell lung cancer(NSCLC)in a short time,but also achieve a lasting response to the tumor.However,there has been significant heterogeneity in the efficacy of ICIs among patients with different types of NSCLC,and there has been still a lack of universal biomarkers to predict the benefit of ICIs treatment.Inflammation has played a definite role in the occurrence and development of tumors,and a variety of inflammatory markers in serum also have become clinical indicators reflecting immune status,such as lactate dehydrogenase,C-reactive protein,serum neutrophils,lymphocytes,platelets and other indicators.These inflammatory markers are easy to obtain and are associated with the prognosis of a variety of solid tumors.